On January 5, 2024, the CME Coalition submitted comments to the Food and Drug Administration (FDA) regarding its recently issued draft guidance for industry regarding communications from firms to health care providers about scientific information on unapproved uses of approved medical products.
The CME Coalition expressed support for the recommended disclosure of firm generated communications while also suggesting an additional requirement that any other company-led education activity prominently disclose the extent of the company’s involvement.
The CME Coalition expressed support for the recommended disclosure of firm generated communications while also suggesting an additional requirement that any other company-led education activity prominently disclose the extent of the company’s involvement.
| cme_fda_guidance_comment_letter_1.05.24.pdf |
